By Victor Weigman, Ph.D., Director, Translational Genomics, Q2 Solutions
Of the 189 oncology therapies under development in the three year period leading up to 2015, 56% had an associated biomarker.1 Nearly 60% of the oncology drugs expected to launch in 2017 will be targeted to biomarker-defined patients. Currently, while (69%) IO clinical trials are focused on single-protein biomarkers, 42% have a genomic component (many in complement to the known protein markers).
Biomarkers For IO Trials
Some of the greatest treatment challenges facing oncologists are matching individuals to therapies while abating treatment resistance. Biomarkers built of the transcriptome can help elucidate which patients have the highest probability of responding to a treatment, and which patients are likely to develop resistance or adverse events based on biochemical pathway incompatibility.
At Q2 Solutions, we use a diverse set of genomic tools for optimizing the use of biomarkers for IO studies. These applications help elucidate the complex interactions between an individual’s cancer and their immune system.